

Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from the 2023 ASH Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following proteins is targeted by the novel agent sonrotoclax?
 - BTK
 - Bcl-2
 - PI3K
 - PP2A
- Which of the following Grade ≥ 3 adverse events was most commonly reported by patients receiving acalabrutinib with obinutuzumab for previously untreated CLL in the 6-year update of the Phase III ELEVATE-TN trial?
 - Neutropenia
 - Blurred vision
 - Hypotension
 - Hemorrhage
- Which of the following best describes outcomes in patients receiving pirtobrutinib for CLL after prior covalent BTK inhibitor therapy in the Phase I/II BRUIN trial?
 - Clinical benefit was observed only in patients with Bcl-2-naïve disease
 - Clinical benefit was observed only in patients with Bcl-2-exposed disease
 - Clinical benefit was observed in both patients with Bcl-2-naïve and Bcl-2-exposed disease
- Which of the following best describes outcomes from the Phase II RT01 trial of tislelizumab in combination with zanubrutinib in patients with Richter's transformation?
 - Primary endpoint of improved overall response rate (ORR) was not met
 - Primary endpoint of improved ORR was met
- Which of the following best describes complete responses (CRs) observed with zanubrutinib in the Phase III ALPINE trial for previously treated CLL/small lymphocytic leukemia?
 - CRs were greatest at 6 months
 - CRs were greatest 12 months
 - CRs were greatest at 24 months
 - CRs deepen over time to 48 months